Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zuranolone

- PMLiVE

Glimmer of hope for amyloid drugs in Alzheimer’s?

Expectations remain high but high efficacy rates still allusive for most firms

EISAI

Eisai to transfer US manufacturing campus to Biogen

Willhand over Research Triangle Park facility incapacity-sharing deal

Biogen promotes Matt Griffiths to chief information officer

He originally joined the firm from Dell earlier this year

- PMLiVE

Pfizer maintains lead in top CNS drug sales – just

But Biogen is looking to take the top spot next year as its MS portfolio grows

Biogen Idec building

Biogen Idec claims first with Alzheimer’s candidate

Aducanumab slowed down impairment in cognition and memory in early stages

- PMLiVE

Biogen Idec launches online multiple sclerosis programme

MS Blueprint aims to help people with MS develop a personalised support plan

- PMLiVE

Otsuka and Lundbeck file Abilify follow-up in the US

Brexpiprazole to be reviewed for use in schizophrenia and major depressive disorder

- PMLiVE

Shire’s ADHD drug fails in depression trial

Company drops Vyvanse for use in major depressive disorder

- PMLiVE

Lilly depression drug fails late-stage trials

Will not pursue edivoxetine as an add-on treatment for depression

- PMLiVE

Pipeline: Major depressive disorder therapeutics

There are limited pipeline prospects to address this significant health issue

- PMLiVE

Lundbeck buoyed by Brintellix approval in US

FDA gives green light for to Cipralex/Lexapro successor in depression

- PMLiVE

Shires’s Jeffrey Jonas to lead Sage

CNS appoints CEO alongside new CMO and CFO

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links